Literature DB >> 26109136

Beta-blocker, angiotensin-converting enzyme inhibitor/angiotensin receptor blocker, nitrate-hydralazine, diuretics, aldosterone antagonist, ivabradine, devices and digoxin (BANDAID(2) ): an evidence-based mnemonic for the treatment of systolic heart failure.

N Chia1,2, J Fulcher1,2,3, A Keech1,2,3.   

Abstract

Heart failure causes significant morbidity and mortality, with recognised underutilisation rates of guideline-based therapies. Our aim was to review current evidence for heart failure treatments and derive a mnemonic summarising best practice, which might assist physicians in patient care. Treatments were identified for review from multinational society guidelines and recent randomised trials, with a primary aim of examining their effects in systolic heart failure patients on mortality, hospitalisation rates and symptoms. Secondary aims were to consider other clinical benefits. MEDLINE and EMBASE were searched using a structured keyword strategy and the retrieved articles were evaluated methodically to produce an optimised reference list for each treatment. We devised the mnemonic BANDAID (2) , standing for beta-blocker, angiotensin-converting enzyme inhibitor/angiotensin receptor blocker, nitrate-hydralazine (or potentially neprilysin inhibitor), diuretics, aldosterone antagonist, ivabradine, devices (automatic implantable cardioverter defibrillator, cardiac resynchronisation therapy or both) and digoxin as a representation of treatments with strong evidence for their use in systolic heart failure. Treatment with omega-3 fatty acids, statins or anti-thrombotic therapies has limited benefits in a general heart failure population. Adoption of this mnemonic for current evidence-based treatments for heart failure may help improve prescribing rates and patient outcomes in this debilitating, high mortality condition.
© 2016 Royal Australasian College of Physicians.

Entities:  

Keywords:  evidence-based medicine; heart failure; pharmacotherapy; prevention; review; treatment

Mesh:

Substances:

Year:  2016        PMID: 26109136     DOI: 10.1111/imj.12839

Source DB:  PubMed          Journal:  Intern Med J        ISSN: 1444-0903            Impact factor:   2.048


  4 in total

1.  The exercise in pulmonary arterial hypertension (ExPAH) study: A randomized controlled pilot of exercise training and multidisciplinary rehabilitation in pulmonary arterial hypertension.

Authors:  Karen S W Chia; Christine T Shiner; Karen Brown; Cameron J Holloway; Camila Moreyra; Nicole Bart; Peter K K Wong; Steven G Faux; Eugene Kotlyar
Journal:  Pulm Circ       Date:  2022-05-11       Impact factor: 2.886

2.  Comparison of the effects of intramyocardial and intravenous injections of human mesenchymal stem cells on cardiac regeneration after heart failure.

Authors:  Behnaz Mokhtari; Nahid Aboutaleb; Donya Nazarinia; Mahin Nikougoftar; Seyed Mohammad Taghi Razavi Tousi; Mohammad Molazem; Mohammad-Reza Azadi
Journal:  Iran J Basic Med Sci       Date:  2020-07       Impact factor: 2.699

3.  SGLT2i versus ARNI in heart failure with reduced ejection fraction: a systematic review and meta-analysis.

Authors:  Yuling Yan; Bin Liu; Jun Du; Jing Wang; Xiaodong Jing; Yajie Liu; Songbai Deng; Jianlin Du; Qiang She
Journal:  ESC Heart Fail       Date:  2021-03-21

4.  Metoprolol and bisoprolol ameliorate hypertrophy of neonatal rat cardiomyocytes induced by high glucose via the PKC/NF-κB/c-fos signaling pathway.

Authors:  Min Wang; Qingbo Lv; Liding Zhao; Yao Wang; Yi Luan; Zhengwei Li; Guosheng Fu; Wenbin Zhang
Journal:  Exp Ther Med       Date:  2019-12-10       Impact factor: 2.447

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.